Physician profile
Daniel J Uderitz
NPI 1295963437
$21,959.22
in general payments reported to CMS, 2019-2025
38 companies · $4,853 in 2025
The $4,853 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,818 · 2020: $2,072 · 2021: $2,580 · 2022: $3,064 · 2023: $3,584 · 2024: $3,988 · 2025: $4,853.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $39.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,385.81 |
| Education | $39.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $2,579.74 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $2,104.74 | 2021-2025 | Vraylar |
| Lundbeck LLC | $1,959.17 | 2019-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $1,691.19 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $1,276.58 | 2021-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $1,263.74 | 2022-2025 | Auvelity, Sunosi |
| Vanda Pharmaceuticals INC. | $1,177.62 | 2020-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,151.53 | 2020-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $1,054.83 | 2019-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $929.74 | 2019-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Corium, LLC | $775.76 | 2022-2025 | Azstarys |
| Allergan, INC. | $735.73 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $667.43 | 2019-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $580.69 | 2024-2025 | Cobenfy |
| Alkermes, INC. | $536.63 | 2020-2025 | Lybalvi, Aristada |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, LP | $498.28 | 2020-2025 | Adzenys Xr-Odt, Exxua |
| Janssen Pharmaceuticals, INC | $457.77 | 2019-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Tris Pharma INC | $318.22 | 2019-2025 | Dyanavel Xr, Quillivant |
| Idorsia Pharmaceuticals US INC | $268.99 | 2022-2025 | Quviviq, Quviviq |
| Eisai INC. | $233.15 | 2020-2022 | |
| Almatica Pharma LLC | $218.68 | 2024-2025 | Loreev Xr |
| Bausch Health US, LLC | $215.29 | 2019-2023 | Aplenzin |
| Ironshore Pharmaceuticals INC. | $187.40 | 2019-2024 | Jornay Pm |
| Avanir Pharmaceuticals, INC. | $181.64 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $138.60 | 2019-2022 | |
| Noven Therapeutics, LLC | $130.42 | 2024-2025 | Xelstrym |
| Adlon Therapeutics L.P. | $105.56 | 2019-2021 | |
| Neuronetics, INC. | $103.71 | 2019-2022 | |
| Harmony Biosciences LLC | $94.87 | 2021-2025 | |
| Sage Therapeutics, LLC | $69.28 | 2024-2025 | Zurzuvae |
| Livanova USA, INC. | $53.02 | 2023-2024 | Vns Therapy Symmetry Model 8103 Generator |
| Collegium Pharmaceutical, INC. | $49.01 | 2025 | Jornay Pm |
| Arbor Pharmaceuticals, INC. | $48.69 | 2019-2020 | |
| Shire North American Group INC | $25.29 | 2019 | |
| Sumitomo Pharma America, INC. | $22.19 | 2023 | Latuda |
| Owp Pharmaceuticals, INC. | $21.51 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $21.37 | 2025 | |
| Alfasigma USA, INC. | $11.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Uderitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.